Document is current
Any future updates will be listed below
-
Authors
Nordenmalm, Sofia
Malmström, Rickard E.
Freyland, Sara
Nilsson Remahl, A. Ingela M
Wirdefeldt, Karin
Ekheden, Isabella
-
Funding
Funding for this research was provided by:
Karolinska Institute
- License Information
-
More Information
Article History
Received: 3 February 2026
Accepted: 28 February 2026
First Online: 10 March 2026
Declaration
:
: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Swedish Ethical Review Authority (initial approval: case number 2021–05078, 2021–10-25; amendments: case number 2022–00372-02, 2022–03-20; 2023–03380-02, 2023–06-08; and 2023–07478-02, 2024–01-05).
: Patient consent was waived by the Swedish Ethical Review Authority after a benefit-risk assessment.
: An earlier version of this study was presented at the European Drug Utilization (EuroDURG) Conference, Uppsala, July 2025 (Abstract number 107, Abstract book page 193, URL: ), and at the 19th European Headache Congress (EHC), Lisbon, December 2025 (Abstract number P399, Abstract book page 245, URL: https://headache-congress.org/programme-abstracts/abstract-booklet-2025/ ).
: The authors Rickard Malmström, A. Ingela M Nilsson Remahl, Karin Wirdefeldt, and Isabella Ekheden are members of Region Stockholm’s Drug and Therapeutics Committee. The remaining authors declare no competing interests.
